Use of dose-dense chemotherapy in the management of breast cancer

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 1, 2006, Pages 36-37

  Norton, Larry ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL; CANCER RELAPSE; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HUMAN; LYMPHOMA; METASTASIS; PREDICTION; TUMOR GROWTH; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL MOVEMENT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FILGRASTIM; HUMANS; NEOPLASM METASTASIS; PACLITAXEL;

EID: 31744435130     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Fornier M, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 2005;7:64-69.
2. Heitjan DF. Generalized Norton-Simon models of tumour growth. Stat Med. 1991;10:1075-1088.
3. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518-524.
4. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist. 2005;10:370-381.